NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News $6.74 +0.08 (+1.20%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$6.28▼$6.7450-Day Range$6.06▼$7.3052-Week Range$2.11▼$13.17Volume4,050 shsAverage Volume9,550 shsMarket Capitalization$29.79 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Corbus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.5% Upside$12.50 Price TargetShort InterestHealthy1.48% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.45Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.52) to ($10.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector279th out of 970 stocksPharmaceutical Preparations Industry111th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Corbus Pharmaceuticals has a forecasted upside of 85.5% from its current price of $6.74.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.48% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently decreased by 13.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Corbus Pharmaceuticals is -0.65. Previous Next 1.9 News and Social Media Coverage News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.73% of the stock of Corbus Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($11.52) to ($10.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corbus Pharmaceuticals (NASDAQ:CRBP) StockCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More CRBP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRBP Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by StockNews.comSeptember 27, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual MeetingOctober 1, 2023 | Behind the Markets (Ad)New Breakthrough "Living Software" Has Been…New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>September 21, 2023 | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by StockNews.com to "Hold"September 19, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 13, 2023 | thestreet.comCorbus Pharmaceuticals (CRBP) Stock Spikes on FDA Fast Track Status DesignationSeptember 10, 2023 | uk.finance.yahoo.comCRBP - Corbus Pharmaceuticals Holdings, Inc.August 9, 2023 | msn.comOppenheimer Reiterates Corbus Pharmaceuticals Holdings (CRBP) Outperform RecommendationOctober 1, 2023 | UNKNOWN (Ad)A Bio-Tech Stock That Has Been Growing Like Crazy!Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn MoreAugust 8, 2023 | finance.yahoo.comCorbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 31, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology ConferenceJune 26, 2023 | seekingalpha.comCorbus Pharmaceuticals to join Russell Microcap indexJune 26, 2023 | finance.yahoo.comCorbus Pharmaceuticals Set to Join Russell Microcap® IndexMay 31, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare ConferenceMay 23, 2023 | fool.comCorbus Pharmaceuticals (NASDAQ: CRBP)May 9, 2023 | msn.comRecap: Corbus Pharmaceuticals Q1 EarningsMay 8, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitorsMay 5, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms marketMay 4, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gainsMay 2, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock falls Tuesday, underperforms marketMay 1, 2023 | finance.yahoo.comCorbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy MeetingApril 25, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitorsApril 18, 2023 | finance.yahoo.comCorbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old TargetMarch 14, 2023 | finance.yahoo.comCorbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual MeetingMarch 13, 2023 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Monday, outperforms marketMarch 7, 2023 | finance.yahoo.comCorbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate UpdateMarch 6, 2023 | finance.yahoo.comCorbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBASee More Headlines Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Company Calendar Last Earnings8/08/2023Today10/01/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees33Year Founded2009Price Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$22.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+85.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.0021) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-183.08% Return on Assets-78.45% Debt Debt-to-Equity Ratio1.19 Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual Sales$880,000.00 Price / Sales33.85 Cash FlowN/A Price / Cash FlowN/A Book Value$7.91 per share Price / Book0.85Miscellaneous Outstanding Shares4,420,000Free Float4,123,000Market Cap$29.79 million OptionableOptionable Beta2.29 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Yuval Cohen Ph.D. (Age 48)CEO & Director Comp: $890.67kMr. Sean F. Moran CPA (Age 65)M.B.A., CPA, MBA, Chief Financial Officer Comp: $579.05kDr. Rachael Brake Ph.D. (Age 51)Chief Scientific Officer Comp: $552.22kTed JenkinsSr. Director of Investor Relations & Corp. CommunicationsMs. Lindsey SmithHead of Corp. Communications & Patient AdvocacyMs. Christina BertschHead of HRMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMQilian International Holding GroupNASDAQ:QLIEledon PharmaceuticalsNASDAQ:ELDNAgeX TherapeuticsNYSE:AGEEnlivex TherapeuticsNASDAQ:ENLVView All CompetitorsInstitutional OwnershipBlackRock Inc.Bought 9,807 shares on 8/11/2023Ownership: 1.854%Dimensional Fund Advisors LPBought 17,919 shares on 8/9/2023Ownership: 0.717%View All Institutional Transactions CRBP Stock - Frequently Asked Questions Should I buy or sell Corbus Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRBP shares. View CRBP analyst ratings or view top-rated stocks. What is Corbus Pharmaceuticals' stock price forecast for 2023? 2 equities research analysts have issued 12 month price targets for Corbus Pharmaceuticals' shares. Their CRBP share price forecasts range from $3.00 to $22.00. On average, they expect the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 85.5% from the stock's current price. View analysts price targets for CRBP or view top-rated stocks among Wall Street analysts. How have CRBP shares performed in 2023? Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of 2023. Since then, CRBP stock has increased by 5,999.5% and is now trading at $6.74. View the best growth stocks for 2023 here. Are investors shorting Corbus Pharmaceuticals? Corbus Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 65,400 shares, a decline of 13.3% from the August 31st total of 75,400 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 5.4 days. Currently, 1.5% of the shares of the stock are short sold. View Corbus Pharmaceuticals' Short Interest. When is Corbus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our CRBP earnings forecast. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($2.05) earnings per share for the quarter, beating the consensus estimate of ($3.10) by $1.05. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB). What is Corbus Pharmaceuticals' stock symbol? Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP." How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corbus Pharmaceuticals' stock price today? One share of CRBP stock can currently be purchased for approximately $6.74. How much money does Corbus Pharmaceuticals make? Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $29.79 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($11.0021) on an earnings per share basis. How can I contact Corbus Pharmaceuticals? Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085. This page (NASDAQ:CRBP) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.